key: cord-1011346-1mepmozc
authors: McCubrey, James A.; Akula, Shaw M.; Payrastre, Bernard
title: Foreword for the special issue advances in COVID-19: Biology and clinic
date: 2020-07-09
journal: Adv Biol Regul
DOI: 10.1016/j.jbior.2020.100744
sha: ef646f46cb5feee03cf9ecd62c125c190a7e994f
doc_id: 1011346
cord_uid: 1mepmozc

nan

In this special issue of Advances in Biological Regulation, there are seven articles which discuss some basic aspects of COVID-19, namely the origins, epidemiology and containment strategies of SARS-CoV-2, the virus responsible for COVID-19, some basic aspects regarding the SARS-CoV-2 genome and replication, the interactions of COVID-19 with the innate and adaptive immune system, the thromoboembolic events associated with COVID-19, the effects of the COVID-19 pandemic on cancer treatments, and the potential of repurposing existing drugs, vitamins, nutraceuticals and trace minerals to treat patients suffering from COVID-19. This special issue attempts to provide a brief overview of COVID-19 and key clinical, immunological, and biological properties of infection with SARS-CoV-2.

In the manuscript by Acuti Matellucci et al., 2020, the origins of SARS-CoV-2 are discussed as well as the modes of transmission and diagnosis, and the epidemiological parameters required to support containment policies. Droplet transmission is believed to be the most effective mode of virus transmission. The duration of the disease in patients with COVID-19 is also discussed. Most infected patients have the capacity to transmit the disease for at least fourteen days, some more than thirty days.

The symptoms may occur approximately two to five days after contact with the SARS-CoV-2 virus.

Most individuals infected with SARS-CoV-2 remain asymptomatic or mildly symptomatic. Patients with severe forms of the disease may die after approximately fourteen days dependent on the therapeutic interventions provided to the patient.

Models have suggested that one person can infect two to six people with the virus. The symptoms of infection can occur after varying time periods of exposure, from two to five days. In a house-hold with an infected individual, the secondary attack rate is predicted to be close to 12%. The authors estimated the average risk of causing severe/lethal COVID-19 in the Italian population and the 2 risks of infecting other people with the virus, and highlighted the necessity of using epidemiological parameters in order to find the most correct, balanced containment strategies, which should take into account also the potential harms of lockdown measures.

Various risk factors have been associated with the morbidity of patients infected with SARS-CoV-2. Risk factors include age (>65 years old), diabetes, obesity, heart disease, sex (higher in males in females), imunosuppression and ABO blood types (higher in A type than O type).

The authors have discussed that the lethality of COVID-19 could be decreasing due to the presented attenuated virus in the population. However, it should be mentioned that this is a virus with a single-stranded RNA genome and may have a high mutation rate which could complicate the development of effective vaccines.

Different types of diagnostic polymerase chain reaction (PCR) are employed to detect the virus. Different PCR primers have been evaluated. Reverse transcriptase PCR (RT-PCR) is a standard assay to detect SARS-CoV-2, however droplet digital PCR may be better than RT-PCR. However, these tools may not be available in certain settings (e.g., patients on cruise ships, or countries with limited resources). Serological tests are also performed to detect antibody responses to viral infection. However, in certain cases, antibodies can only be detected weeks after infection. The COVID-19 pandemic has affected certain "standard" operating protocols in the hematology department such as the scheduling of certain procedures such as transplantations, blood collections and transfusions and other operations. Some common treatments (e.g., treatment with certain chemotherapeutic or immunosuppressive drugs) have been delayed as they are immunosuppressive in nature, and it is important to prevent the infection of hematological patients with SARS-CoV-2. This is summarized in a review by Finneli and Parisi in hematological settings. Certain hematological conditions such thrombocytopenia, lymphopenia and coagulation abnormalities, may be useful for the prognostic evaluation of SARS-CoV-2-infected patients.

In the review by Akula et al., the effects of the COVID-19 pandemic on various cancer treatments are discussed. Although there have been tendencies to delay cancer treatments or screening when possible this is not always the optimal clinical protocol. In some cases, increased doses of cancer inhibitors have been prescribed into order to prevent multiple trips to the hospital and reduce the potential for patient exposure to SARS-CoV-2. The problems associated with sterility and prevention of infections in the operating room are considered. This review also discussed some of the approaches used 5 to identify cellular targets of SARS-CoV-2 which may allow the use of more specific targeted therapeutics. This review also discusses the repurposing of existing FDA-approved drugs to treat COVID-19 patients. Finally, the use of vitamins, nutraceuticals and trace minerals in prevention of infection and treatment of COVID-19 patients is considered.

SARS-CoV-2 pandemic: an overview

Where are we with understanding of COVID-19

Cancer Therapy and Treatments During COVID-19 Era

The clinical impact of COVID-19 epidemic in the hematologic setting

NK cells: a double edge sword against SARS-CoV-2

Thromboembolic events and Covid-19

Devilishly radical NETwork in COVID-19: oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression